Jan 19, 2026
What were the design flaws and subgroup analyses in TauRx’s earlier LMTM Phase III trials?
TauRx’s earlier Phase III trials of LMTM (leuco‑methylthioninium/HMTM/LMTX) repeatedly failed their prespecified primary endpoints, but the company highlighted statistically significant effects in sma...